683 Capital Management’s Evoke Pharma EVOK Stock Holding History

683 Capital Management’s Portfolio EVOK Stock Details EVOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-794	Closed	-$283K	–	172
2018 Q4	$283K	Hold	794	–	–	0.02%	131
2018 Q3	$341K	Hold	794	–	–	0.02%	116
2018 Q2	$286K	Hold	794	–	–	0.02%	120
2018 Q1	$238K	Hold	794	–	–	0.02%	118
2017 Q4	$258K	Buy	+794	New	+$329K	0.02%	130

Other funds holding EVOK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

683 Capital Management's EVOK Position: Q1 2019 in Review

683 Capital Management sold out of Evoke Pharma (EVOK) in Q1 2019, closing a stake of 794 shares — an estimated $283K sold.

683 Capital Management first reported a position in EVOK in Q4 2017 and held it in 5 quarters. The position peaked at $341K in Q3 2018. 22 funds tracked by Wall St. Rank hold EVOK as of Q1 2019.

683 Capital Management reported no remaining Evoke Pharma position as of Q1 2019 after selling out during the quarter.
683 Capital Management sold 794 Evoke Pharma shares in Q1 2019, an estimated $283K.
683 Capital Management first reported a position in Evoke Pharma in Q4 2017 and held it in 5 quarters.
683 Capital Management's Evoke Pharma position peaked at $341K in Q3 2018.
22 funds tracked by Wall St. Rank held Evoke Pharma as of Q1 2019.

Based on 683 Capital Management's 13F filing for Q1 2019, filed 15 May 2019.